Shanxi province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia

被引:258
作者
Belinson, J
Qiao, YL
Pretorius, R
Zhang, WH
Elson, P
Li, L
Pan, QJ
Fischer, C
Lorincz, A
Zahniser, D
机构
[1] Cleveland Clin Fdn, Dept Gynecol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA
[4] Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100021, Peoples R China
[5] Kaiser Permanente, Dept Gynecol Oncol & Pelv Surg, Fontana, CA 92335 USA
[6] Opt Biopsy Technol LLC, Knoxville, TN 37902 USA
[7] Digene Corp, Gaithersburg, MD 20878 USA
[8] Cytyc Corp, Boxboro, MA 01719 USA
关键词
cervical; cancer; screening; developing world; HPV; cytology; visual inspection; spectroscopy;
D O I
10.1006/gyno.2001.6370
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of this study was to design a cervical cancer screening algorithm for the developing world that is highly sensitive for cervical intraepithelial neoplasia (CIN) II, III, and cancer and highly specific for CIN II and III, making it possible to ablate the transformation zone without histologic confirmation. Methods. In rural Shanxi Province, China, we examined 1997 women ages 35-45. Each subject underwent a self-test for intermediate and high-risk HPV (by HC-II assay), fluorescence spectroscopy, a liquid-based Pap (read manually and by computer and used as a direct test for HPV), a visual inspection (VIA) diagnosis, and colposcopy with multiple cervical biopsies. Results. Mean age was 39.1 +/- 3.16 years, mean number of births was 2.6 +/- 0.93. Based on tests administered, 4.3% subjects had greater than or equal to CIN II. All subjects with greater than or equal to CIN II had either a ThinPrep ap, (greater than or equal to ASCUS) or a positive HPV direct test. The sensitivity and specificity for the detection of greater than or equal to CIN II were, respectively, 83 and 86% for the HPV self-test, 95 and 85% for the HPV direct test, 94 and 78% for the ThinPrep Pap (greater than or equal to ASCUS), 77 and 98% for the ThinPrep Pap ( greater than or equal to HGSIL), 94 and 9% for fluorescence spectroscopy, 71 and 74% for VIA, and 81 and 77% for colposcopy. Conclusion. Based on these data and the existing healthcare infrastructure in China, we believe that further refinement of primary HPV screening using centralized labs is indicated. Self-testing in the local villages may be effective with improvements in the devices and techniques. (C) 2001 Academic Press.
引用
收藏
页码:439 / 444
页数:6
相关论文
共 25 条
[1]  
*AG HLTH CAR POL R, 1999, PUBL
[2]  
Agrawal A, 1999, LASER SURG MED, V25, P237, DOI 10.1002/(SICI)1096-9101(1999)25:3<237::AID-LSM8>3.0.CO
[3]  
2-F
[4]   Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study [J].
Belinson, J ;
Qiao, Y ;
Pretorius, R ;
Zhang, W ;
Keaton, K ;
Elson, P ;
Fischer, C ;
Lorincz, A ;
Zahniser, D ;
Wilbur, D ;
Pan, Q ;
Li, L ;
Biscotti, C ;
Dawson, A ;
Li, A ;
Wu, L ;
Ling, Y ;
Ma, CP ;
Yang, XP .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1999, 9 (05) :411-417
[5]   Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system [J].
Bolick, DR ;
Hellman, DJ .
ACTA CYTOLOGICA, 1998, 42 (01) :209-213
[6]   Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions [J].
Clavel, C ;
Masure, M ;
Putaud, I ;
Thomas, I ;
Bory, JP ;
Gabriel, R ;
Quereux, C ;
Birembaut, P .
JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (10) :737-740
[7]   Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women [J].
Clavel, C ;
Masure, M ;
Bory, JP ;
Putaud, I ;
Mangeonjean, C ;
Lorenzato, M ;
Gabriel, R ;
Quereux, C ;
Birembaut, P .
BRITISH JOURNAL OF CANCER, 1999, 80 (09) :1306-1311
[8]  
DeMay RM, 1997, ARCH PATHOL LAB MED, V121, P229
[9]  
Li L. D., 1996, CHINESE J ONCOL, V18, P403
[10]  
LI LD, 1997, CHINESE J ONCOL, V19, P3